Thanks to a central coordination and operational support team, OPALE serves as a single destination for industry’s developments of new solutions for the treatment and diagnosis of leukemias and related diseases, regardless of partner’s size, nationality or project type. OPALE’s partnering offer ranges from the identification of novel therapeutic targets to RWE studies, going through preclinical, translational and clinical developments, including access to drug discovery, drug screening, clinical batches bioproduction and immuno-monitoring platforms, as well as to unique patient databases and annotated biocollections.